Passage Bio, Inc. Stock Price, News & Analysis

Passage Bio (NASDAQ: PASG) reported promising interim data for PBGM01 in GM1 gangliosidosis during the 19th Annual WORLDSymposium™, showing a biological effect in the first six patients. The company plans to expand the Imagine-1 study to include higher doses and expects initial safety data from Cohort 4 by mid-2023. Financial results highlighted a cash position of $189.6 million, sufficient to fund operations through the first half of 2025. The net loss for Q4 2022 stood at $27.1 million, while R&D expenses decreased to $17.7 million. The company anticipates key results from its upliFT-D trial in FTD by late 2023.

Passage Bio, a clinical-stage genetic medicines company (Nasdaq: PASG), announces the opening of its Tachi Yamada Scholarship program for rising juniors majoring in life sciences at Pennsylvania colleges. The $10,000 scholarship, awarded annually, aims to support students committed to careers in life sciences. Applications are due by April 1, 2023, for the initial award in fall 2023. The scholarship honors the legacy of Dr. Tachi Yamada, co-founder and former chairman of the board, who championed mentorship in the field. The selected scholar will also receive mentorship opportunities over two years for professional development.

Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company, announced CEO William Chou will participate in a corporate panel at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 10:30 a.m. ET in Boston, MA. This event will focus on therapies for central nervous system disorders. A live webcast will be accessible on Passage Bio's website, with a replay available for 30 days post-event. The company is advancing treatments for CNS diseases, including GM1 gangliosidosis and frontotemporal dementia, leveraging a collaboration with the University of Pennsylvania's Gene Therapy Program.

Passage Bio (NASDAQ: PASG) announced a conference call on March 6, 2023, at 8:30 a.m. ET to discuss its Q4 and full-year 2022 financial results and recent business developments. The company focuses on developing gene therapies for central nervous system disorders, including GM1 gangliosidosis and frontotemporal dementia. Through a collaboration with the University of Pennsylvania’s Gene Therapy Program, Passage Bio enhances its access to gene therapy candidates, leveraging its clinical and regulatory expertise. Investors can access the webcast on the company's website post-event.

Passage Bio, Inc. (Nasdaq: PASG) announced new data from its Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis, presented at the 19th Annual WORLD Symposium. The updated interim results indicate that PBGM01 administration led to stabilization of MRI severity scores in all treated patients over a follow-up of 6 to 12 months, suggesting positive biological effects. Additionally, decreases in urine levels of β-Gal substrate Dp5 were observed, indicating increased β-Gal activity. The therapy shows a favorable safety profile with no serious adverse events reported, bolstering confidence in PBGM01 as a potential treatment option for this rare disease.

Passage Bio has announced its participation in the 19th Annual WORLD Symposium™ from February 22-26, 2023, in Orlando, Florida, where it will share updated interim data from the Phase 1/2 Imagine-1 study of PBGM01 for GM1 gangliosidosis. The presentations by Jeanine Jarnes, Pharm D., from the University of Minnesota, are scheduled for February 24, 2023, with the oral presentation at 2:00 p.m. ET and a poster session at 3:00 p.m. ET. PBGM01, a gene therapy using AAV technology, targets GM1 gangliosidosis, a rare lysosomal storage disorder affecting the CNS. The FDA has granted it several designations, including Fast Track and Orphan Drug.

On January 20, 2023, Passage Bio (Nasdaq: PASG) announced the granting of stock options to a new employee as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options, totaling 7,600 shares, have an exercise price of $1.67 per share, equal to its closing price on the grant date, January 17, 2023. These stock options will vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments thereafter. Passage Bio focuses on developing therapies for CNS disorders with ongoing clinical programs targeting conditions like GM1 gangliosidosis and frontotemporal dementia.

Passage Bio (NASDAQ: PASG) provided interim safety and biomarker results from its Phase 1/2 Imagine-1 clinical study of PBGM01 in pediatric patients with GM1 Gangliosidosis. The low and high doses of PBGM01 were well tolerated, with no serious adverse events reported. The therapy showed promising results, including dose-dependent increases in CSF β-Gal activity and decreases in GM1 gangliosides. Initial results from the completed dosing of Cohort 4 are expected by mid-2023, highlighting the ongoing development of this potential treatment.

Passage Bio, Inc. (NASDAQ: PASG) has provided updates on its clinical trials and financial results for Q3 2022. The company dosed the first patient in the final cohort of the Imagine-1 trial for GM1 gangliosidosis and the upliFT-D trial for frontotemporal dementia. While cash reserves were $213.8 million, R&D expenses decreased to $15.4 million, and G&A expenses dropped to $10.7 million. Despite a net loss of $26.7 million, the cash runway is extended into 2025. The company plans to present safety data in December 2022 and refocus on key trials.